Horm Metab Res 2015; 47(13): 967-972
DOI: 10.1055/s-0035-1565225
Review

Steroid Hormone Production in Patients with Aldosterone Producing Adenomas

M. Moors
1   Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
,
T. A. Williams
2   Division of Internal Medicine and Hypertension, Department of Medical Sciences, University of Turin, Turin, Italy
3   Medizinische Klinik und Poliklinik IV, Klinikum der Ludwig-Maximilians-Universität München, Munich, Germany
,
J. Deinum
1   Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
,
G. Eisenhofer
4   Institute of Clinical Chemistry and Laboratory Medicine, Technische Universität Dresden, Dresden, Germany
5   Department of Internal Medicine III, Technische Universität Dresden, Dresden, Germany
,
M. Reincke
3   Medizinische Klinik und Poliklinik IV, Klinikum der Ludwig-Maximilians-Universität München, Munich, Germany
,
J. W. M. Lenders
1   Department of Internal Medicine, Radboud University Medical Center, Nijmegen, The Netherlands
5   Department of Internal Medicine III, Technische Universität Dresden, Dresden, Germany
› Institutsangaben

Abstract

Primary aldosteronism encompasses 2 major underlying causes: (1) aldosterone producing adenoma and (2) bilateral adrenal hyperplasia. In addition to the aldosterone excess, increased production of other compounds of the steroidogenic pathways may be involved. Until recently, most studies examined the production of steroids other than aldosterone in tumor tissue, urine, or peripheral plasma samples, but several new studies have also addressed steroid levels in adrenal venous blood samples using liquid chromatography tandem mass spectrometry. Plasma and tissue levels of several precursors of aldosterone with mineralocorticoid activity are higher in patients with aldosterone producing adenomas than in those with bilateral hyperplasia. These include corticosterone, deoxycorticosterone, and their 18-hydroxylated metabolites. Similarly, urinary, peripheral, and adrenal venous concentrations of the hybrid steroids 18-oxocortisol and 18-hydroxycortisol are higher in patients with aldosterone producing adenomas than in bilateral hyperplasia. Differences in the pathophysiology and in clinical and biochemical phenotypes caused by aldosterone producing adenomas and bilateral adrenal hyperplasia may be related to the differential expression of steroidogenic enzymes, and associated to specific underlying somatic mutations. Correct appreciation of differences in steroid profiling between aldosterone producing adenomas and bilateral adrenal hyperplasia may not only contribute to a better understanding of the pathogenesis of primary aldosteronism but may also be helpful for future subtyping of primary aldosteronism.



Publikationsverlauf

Eingereicht: 20. August 2015

Angenommen: 03. November 2015

Artikel online veröffentlicht:
14. Dezember 2015

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • References

  • 1 Miller WL, Auchus RJ. The molecular biology, biochemistry, and physiology of human steroidogenesis and its disorders. Endocr Rev 2011; 32: 81-151
  • 2 Bollag WB. Regulation of aldosterone synthesis and secretion. Compr Physiol 2014; 4: 1017-1055
  • 3 Spät A, Hunyady L. Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev 2004; 84: 489-539
  • 4 Gomez-Sanchez CE, Qi X, Velarde-Miranda C, Plonczynski MW, Parker CR, Rainey W, Satoh F, Maekawa T, Nakamura Y, Sasano H. Development of monoclonal antibodies against human CYP11B1 and CYP11B2. Mol Cell Endocrinol 2014; 383: 111-117
  • 5 Nishimoto K, Tomlins SA, Kuick R, Cani AK, Giordano TJ, Hovelson DH, Liu CJ, Sanjanwala AR, Edwards MA, Gomez-Sanchez CE, Nanba K, Rainey WE. Aldosterone-stimulating somatic gene mutations are common in normal adrenal glands. Proc Natl Acad Sci USA 2015; 112: E4591-E4599
  • 6 Doi M, Takahashi Y, Komatsu R, Yamazaki F, Yamada H, Haraguchi S, Emoto N, Okuno Y, Tsujimoto G, Kanematsu A, Ogawa O, Todo T, Tsutsui K, van der Horst GT, Okamura H. Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. Nat Med 2010; 16: 67-74
  • 7 Rossi GP. A comprehensive review of the clinical aspects of primary aldosteronism. Nat Rev Endocrinol 2011; 7: 485-495
  • 8 Young WF. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol 2007; 66: 607-618
  • 9 SASANO H. Localization of steroidogenic enzymes in adrenal cortex and its disorders. Endocr J 1994; 41: 471-482
  • 10 Boulkroun S, Samson-Couterie B, Dzib J-FG, Lefebvre H, Louiset E, Amar L, Plouin P-F, Lalli E, Jeunemaitre X, Benecke A. Adrenal cortex remodeling and functional zona glomerulosa hyperplasia in primary aldosteronism. Hypertension 2010; 56: 885-892
  • 11 Ulick S, Chu MD, Land M. Biosynthesis of 18-oxocortisol by aldosterone-producing adrenal tissue. J Biol Chem 1983; 258: 5498-5502
  • 12 Freel EM, Shakerdi LA, Friel EC, Wallace AM, Davies E, Fraser R, Connell JM. Studies on the origin of circulating 18-hydroxycortisol and 18-oxocortisol in normal human subjects. J Clin Endocrinol Metab 2004; 89: 4628-4633
  • 13 Sakuma I, Suematsu S, Matsuzawa Y, Saito J, Omura M, Maekawa T, Nakamura Y, Sasano H, Nishikawa T. Characterization of steroidogenic enzyme expression in aldosterone-producing adenoma: a comparison with various human adrenal tumors. Endocr J 2013; 60: 329-336
  • 14 Nakamura Y, Maekawa T, Felizola SJ, Satoh F, Qi X, Velarde-Miranda C, Plonczynski MW, Ise K, Kikuchi K, Rainey WE. Adrenal CYP11B1/2 expression in primary aldosteronism: immunohistochemical analysis using novel monoclonal antibodies. Mol Cell Endocrinol 2014; 392: 73-79
  • 15 Gioco F, Seccia TM, Gomez-Sanchez EP, Rossi GP, Gomez-Sanchez CE. Adrenal histopathology in primary aldosteronism: Is it time for a change?. Hypertension 2015; 66: 724-730
  • 16 Monticone S, Castellano I, Versace K, Lucatello B, Veglio F, Gomez-Sanchez CE, Williams TA, Mulatero P. Immunohistochemical, genetic and clinical characterization of sporadic aldosterone-producing adenomas. Mol Cell Endocrinol 2015; 411: 146-154
  • 17 Ono Y, Nakamura Y, Maekawa T, Felizola SJ, Morimoto R, Iwakura Y, Kudo M, Seiji K, Takase K, Arai Y, Gomez-Sanchez CE, Ito S, Sasano H, Satoh F. Different expression of 11beta-hydroxylase and aldosterone synthase between aldosterone-producing microadenomas and macroadenomas. Hypertension 2014; 64: 438-444
  • 18 Wang T, Satoh F, Morimoto R, Nakamura Y, Sasano H, Auchus RJ, Edwards MA, Rainey WE. Gene expression profiles in aldosterone-producing adenomas and adjacent adrenal glands. Eur J Endocrinol 2011; 164: 613-619
  • 19 Konosu-Fukaya S, Nakamura Y, Satoh F, Felizola SJ, Maekawa T, Ono Y, Morimoto R, Ise K, Takeda K, Katsu K, Fujishima F, Kasajima A, Watanabe M, Arai Y, Gomez-Sanchez EP, Gomez-Sanchez CE, Doi M, Okamura H, Sasano H. 3beta-hydroxysteroid dehydrogenase isoforms in human aldosterone-producing adenoma. Mol Cell Endocrinol 2015; 408: 205-212
  • 20 Doi M, Satoh F, Maekawa T, Nakamura Y, Fustin J-M, Tainaka M, Hotta Y, Takahashi Y, Morimoto R, Takase K, Ito S, Sasano H, Okamura H. Isoform-specific monoclonal antibodies against 3b-hydroxysteroid dehydrogenase/isomerase family provide markers for subclassification of human primary aldosteronism. J Clin Endocrinol Metab 2014; 99: E257-E262
  • 21 Doi M, Satoh F, Maekawa T, Nakamura Y, Fustin JM, Tainaka M, Hotta Y, Takahashi Y, Morimoto R, Takase K, Ito S, Sasano H, Okamura H. Isoform-specific monoclonal antibodies against 3beta-hydroxysteroid dehydrogenase/isomerase family provide markers for subclassification of human primary aldosteronism. J Clin Endocrinol Metab 2014; 99: E257-E262
  • 22 Monticone S, Else T, Mulatero P, Williams TA, Rainey WE. Understanding primary aldosteronism: impact of next generation sequencing and expression profiling. Mol Cell Endocrinol 2015; 399: 311-320
  • 23 Fernandes-Rosa FL, Williams TA, Riester A, Steichen O, Beuschlein F, Boulkroun S, Strom TM, Monticone S, Amar L, Meatchi T. Genetic spectrum and clinical correlates of somatic mutations in aldosterone-producing adenoma. Hypertension 2014; 64: 354-361
  • 24 Beuschlein F, Boulkroun S, Osswald A, Wieland T, Nielsen HN, Lichtenauer UD, Penton D, Schack VR, Amar L, Fischer E, Walther A, Tauber P, Schwarzmayr T, Diener S, Graf E, Allolio B, Samson-Couterie B, Benecke A, Quinkler M, Fallo F, Plouin PF, Mantero F, Meitinger T, Mulatero P, Jeunemaitre X, Warth R, Vilsen B, Zennaro MC, Strom TM, Reincke M. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet 2013; 45: 440-444
  • 25 Boulkroun S, Golib Dzib JF, Samson-Couterie B, Rosa FL, Rickard AJ, Meatchi T, Amar L, Benecke A, Zennaro MC. KCNJ5 mutations in aldosterone producing adenoma and relationship with adrenal cortex remodeling. Mol Cell Endocrinol 2013; 371: 221-227
  • 26 Williams TA, Monticone S, Schack VR, Stindl J, Burrello J, Buffolo F, Annaratone L, Castellano I, Beuschlein F, Reincke M, Lucatello B, Ronconi V, Fallo F, Bernini G, Maccario M, Giacchetti G, Veglio F, Warth R, Vilsen B, Mulatero P. Somatic ATP1A1, ATP2B3, and KCNJ5 mutations in aldosterone-producing adenomas. Hypertension 2014; 63: 188-195
  • 27 Azizan EA, Lam BY, Newhouse SJ, Zhou J, Kuc RE, Clarke J, Happerfield L, Marker A, Hoffman GJ, Brown MJ. Microarray, qPCR, and KCNJ5 sequencing of aldosterone-producing adenomas reveal differences in genotype and phenotype between zona glomerulosa-and zona fasciculata-like tumors. J Clin Endocrinol Metab 2012; 97: E819-E829
  • 28 Azizan EA, Poulsen H, Tuluc P, Zhou J, Clausen MV, Lieb A, Maniero C, Garg S, Bochukova EG, Zhao W. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet 2013; 45: 1055-1060
  • 29 Williams TA, Peitzsch M, Dietz AS, Dekkers T, Bidlingmaier M, Riester A, Treitl M, Rhayem Y, Beuschlein F, Lenders JWM, Deinum J, Eisenhofer G, Reincke M. Genotype-specific steroid profiles associated with aldosterone-producing adenomas. Hypertension. 2015 Nov 16. pii: HYPERTENSIONAHA.115.06186. [Epub ahead of print]
  • 30 Dekkers T, Ter Meer M, Lenders J, Hermus A, Schultze Kool L, Langenhuijsen J, Nishimoto K, Ogishima T, Mukai K, Azizan E. Adrenal nodularity and somatic mutations in primary aldosteronism: one node is the culprit?. J Clin Endocrinol Metab 2014; 99: E1341-E1351
  • 31 Biglieri EG, Hane S, Slaton Jr PE, Forsham PH. In vivo and in vitro studies of adrenal secretions in Cushing’s syndrome and primary aldosteronism. J Clin Invest 1963; 42: 516-524
  • 32 Louis LH, Conn JW. Primary aldosteronism: content of adrenocortical steroids in adrenal tissue. Recent Prog Horm Res 1961; 17: 415-436
  • 33 Kaplan NM. The steroid content of adrenal adenomas and measurements of aldosterone production in patients with essential hypertension and primary aldosteronism. J Clin Invest 1967; 46: 728-734
  • 34 Glaz E, Racz K, Varga I, Kiss R, Toth M, Futo L. Mineralocorticoid production of adrenal cortical adenomas. J Steroid Biochem Mol Biol 1993; 45: 57-64
  • 35 Takeda Y, Lewicka S, Koch S, Bige K, Vecsei P, Abdelhamid S, Cojocaru M, Harnik M. Synthesis of 19-nor-aldosterone, 18-hydroxy-19-nor-corticosterone and 18,19-dihydroxycorticosterone in the human aldosterone-producing adenoma. J Steroid Biochem Mol Biol 1990; 37: 599-604
  • 36 Irony I, Kater CE, Biglieri EG, Shackleton CH. Correctable subsets of primary aldosteronism. Primary adrenal hyperplasia and renin responsive adenoma. Am J Hypertens 1990; 3: 576-582
  • 37 Kem DC, Tang K, Hanson CS, Brown RD, Painton R, Weinberger MH, Hollifield JW. The prediction of anatomical morphology of primary aldosteronism using serum 18-hydroxycorticosterone levels. J Clin Endocrinol Metab 1985; 60: 67-73
  • 38 Biglieri EG, Schambelan M. The significance of elevated levels of plasma 18-hydroxycorticosterone in patients with primary aldosteronism. J Clin Endocrinol Metab 1979; 49: 87-91
  • 39 Mulatero P, di Cella SM, Monticone S, Schiavone D, Manzo M, Mengozzi G, Rabbia F, Terzolo M, Gomez-Sanchez EP, Gomez-Sanchez CE. 18-hydroxycorticosterone, 18-hydroxycortisol, and 18-oxocortisol in the diagnosis of primary aldosteronism and its subtypes. J Clin Endocrinol Metab 2012; 97: 881-889
  • 40 Ulick S, Blumenfeld JD, Atlas SA, Wang JZ, Vaughan Jr ED. The unique steroidogenesis of the aldosteronoma in the differential diagnosis of primary aldosteronism. J Clin Endocrinol Metab 1993; 76: 873-878
  • 41 Shackleton C. Clinical steroid mass spectrometry: a 45-year history culminating in HPLC-MS/MS becoming an essential tool for patient diagnosis. J Steroid Biochem Mol Biol 2010; 121: 481-490
  • 42 Kushnir MM, Rockwood AL, Roberts WL, Yue B, Bergquist J, Meikle AW. Liquid chromatography tandem mass spectrometry for analysis of steroids in clinical laboratories. Clin Biochem 2011; 44: 77-88
  • 43 Peitzsch M, Dekkers T, Haase M, Sweep FC, Quack I, Antoch G, Siegert G, Lenders JW, Deinum J, Willenberg HS, Eisenhofer G. An LC-MS/MS method for steroid profiling during adrenal venous sampling for investigation of primary aldosteronism. J Steroid Biochem Mol Biol 2015; 145: 75-84
  • 44 Mosso L, Gomez-Sanchez CE, Foecking MF, Fardella C. Serum 18-hydroxycortisol in primary aldosteronism, hypertension, and normotensives. Hypertension 2001; 38: 688-691
  • 45 Satoh F, Morimoto R, Ono Y, Iwakura Y, Omata K, Kudo M, Takase K, Seiji K, Sasamoto H, Honma S. Measurement of peripheral plasma 18-oxocortisol can discriminate unilateral adenoma from bilateral diseases in patients with primary aldosteronism. Hypertension 2015; 65: 1096-1102
  • 46 Auchus RJ, Chandler DW, Singeetham S, Chokshi N, Nwariaku FE, Dolmatch BL, Holt SA, Wians Jr FH, Josephs SC, Trimmer CK, Lopera J, Vongpatanasin W, Nesbitt SD, Leonard D, Victor RG. Measurement of 18-hydroxycorticosterone during adrenal vein sampling for primary aldosteronism. J Clin Endocrinol Metab 2007; 92: 2648-2651
  • 47 Nakamura Y, Satoh F, Morimoto R, Kudo M, Takase K, Gomez-Sanchez CE, Honma S, Okuyama M, Yamashita K, Rainey WE. 18-oxocortisol measurement in adrenal vein sampling as a biomarker for subclassifying primary aldosteronism. J Clin Endocrinol Metab 2011; 96: E1272-E1278
  • 48 Nakamura Y, Rege J, Satoh F, Morimoto R, Kennedy MR, Ahlem CN, Honma S, Sasano H, Rainey WE. Liquid chromatography-tandem mass spectrometry analysis of human adrenal vein corticosteroids before and after adrenocorticotropic hormone stimulation. Clin Endocrinol 2012; 76: 778-784
  • 49 Rege J, Nakamura Y, Satoh F, Morimoto R, Kennedy MR, Layman LC, Honma S, Sasano H, Rainey WE. Liquid chromatography-tandem mass spectrometry analysis of human adrenal vein 19-carbon steroids before and after ACTH stimulation. J Clin Endocrinol Metab 2013; 98: 1182-1188